Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Presatovir in HCT recipients with RSV LRTI
NCT02254421Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing Presatovir with Placebo (2 arms). Primary endpoint: Time-weighted Average Change in Nasal Respiratory Syncytial Viral (RSV) Load From Baseline to Day 9. Started Jan 2015; status: completed.
02
Drugs
presatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02254421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254421.